Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
JNJ-79032421 by Johnson & Johnson for Malignant Pleural Mesothelioma: Likelihood of Approval
JNJ-79032421 is under clinical development by Johnson & Johnson and currently in Phase I for Malignant Pleural Mesothelioma. According to...
JNJ-79032421 by Johnson & Johnson for Epithelial Ovarian Cancer: Likelihood of Approval
JNJ-79032421 is under clinical development by Johnson & Johnson and currently in Phase I for Epithelial Ovarian Cancer. According to...
JNJ-79032421 by Johnson & Johnson for Peritoneal Cancer: Likelihood of Approval
JNJ-79032421 is under clinical development by Johnson & Johnson and currently in Phase I for Peritoneal Cancer. According to GlobalData,...
JNJ-79032421 by Johnson & Johnson for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
JNJ-79032421 is under clinical development by Johnson & Johnson and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to...
JNJ-79032421 by Johnson & Johnson for Malignant Mesothelioma: Likelihood of Approval
JNJ-79032421 is under clinical development by Johnson & Johnson and currently in Phase I for Malignant Mesothelioma. According to GlobalData,...
JNJ-79032421 by Johnson & Johnson for Fallopian Tube Cancer: Likelihood of Approval
JNJ-79032421 is under clinical development by Johnson & Johnson and currently in Phase I for Fallopian Tube Cancer. According to...